BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23676603)

  • 21. Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy.
    Mao Y; Yin L; Huang H; Zhou Z; Chen T; Zhou W
    J Int Med Res; 2019 Jan; 47(1):105-113. PubMed ID: 30208769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine.
    Fu YF; Liu GL
    Clin Nephrol; 2001 Apr; 55(4):318-21. PubMed ID: 11334319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mizoribine for the treatment of lupus nephritis in children and adolescents.
    Tanaka H; Tsugawa K; Tsuruga K; Suzuki K; Nakahata T; Ito E; Waga S
    Clin Nephrol; 2004 Dec; 62(6):412-7. PubMed ID: 15630899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.
    Ikeuchi H; Hiromura K; Takahashi S; Mishima K; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Kuroiwa T; Nojima Y
    Mod Rheumatol; 2014 Jul; 24(4):618-25. PubMed ID: 24252014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
    Grootscholten C; Ligtenberg G; Hagen EC; van den Wall Bake AW; de Glas-Vos JW; Bijl M; Assmann KJ; Bruijn JA; Weening JJ; van Houwelingen HC; Derksen RH; Berden JH;
    Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
    Szeto CC; Kwan BC; Lai FM; Tam LS; Li EK; Chow KM; Gang W; Li PK
    Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil for lupus nephritis: an update.
    Mok CC
    Expert Rev Clin Immunol; 2015; 11(12):1353-64. PubMed ID: 26364748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB; Won S; Bae SC
    Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Advances in Treatment Strategies for Lupus Nephritis.
    Karasawa K; Uchida K; Takabe T; Moriyama T; Nitta K
    Contrib Nephrol; 2018; 195():42-50. PubMed ID: 29734149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cyclophosphamide-induced lupus flare in diffuse proliferative lupus nephropathy].
    Heras M; Saiz A; Fernández-Reyes MJ; Sánchez R; Zurita P; Urrego C
    Nefrologia; 2011; 31(2):231-3. PubMed ID: 21461001
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
    Gulati A; Sinha A; Gupta A; Kanitkar M; Sreenivas V; Sharma J; Mantan M; Agarwal I; Dinda AK; Hari P; Bagga A
    Kidney Int; 2012 Nov; 82(10):1130-5. PubMed ID: 22763815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
    Aragon E; Resontoc LP; Chan YH; Lau YW; Tan PH; Loh HL; Ng KH; Yap HK
    Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy.
    Opastirakul S; Chartapisak W
    Pediatr Nephrol; 2005 Dec; 20(12):1750-5. PubMed ID: 16133037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide.
    Benenson E; Fries JW; Heilig B; Pollok M; Rubbert A
    Clin Rheumatol; 2005 Jun; 24(3):251-7. PubMed ID: 15940558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective treatment with cyclosporine A of a child with systemic lupus erythematosus resistant to cyclophosphamide pulse therapy.
    Suzuki K; Tanaka H; Tsugawa K; Ito E
    Tohoku J Exp Med; 2006 Apr; 208(4):355-9. PubMed ID: 16565599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Kronbichler A; Neumann I; Mayer G
    Nephrol Dial Transplant; 2016 Oct; 31(10):1572-6. PubMed ID: 27591329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
    Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
    Liu Z; Zhang H; Liu Z; Xing C; Fu P; Ni Z; Chen J; Lin H; Liu F; He Y; He Y; Miao L; Chen N; Li Y; Gu Y; Shi W; Hu W; Liu Z; Bao H; Zeng C; Zhou M
    Ann Intern Med; 2015 Jan; 162(1):18-26. PubMed ID: 25383558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
    Lanata CM; Mahmood T; Fine DM; Petri M
    Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.